Case-By-Case Changes To Off-label Promotion
This article was originally published in RPM Report
Executive Summary
While FDA has stuck to a narrow interpretation of precedents like the Caronia ruling, arguing that the decision does not in any way change the landscape for off-label promotion, a series of subsequent court decisions used the Second Circuit’s precedent to solidify company’s free speech protections.
You may also be interested in...
Vascular Solutions Not-Guilty Verdict Another Challenge To FDA Off-Label Oversight
The case against the venous device manufacturer turned on the rights of manufacturers to use truthful off-label speech to promote their products. It joins a growing body of cases in which courts have sanctioned broader off-label speech than has traditionally been allowed by FDA.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.